Fusion proteins for the treatment of cardiometabolic diseases
AssigneeShattuck Labs, Inc.
InventorsTaylor SCHREIBER, George FROMM
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to, inter alia, compositions and pharmaceutical composition s, including heterologous chimeric proteins that find use, inter alia, in the treatment of diabetes, obesity, or metabolic syndrome.
Claims21
-278. (canceled)
A method of treating or preventing diabetes or obesity in a subject in need thereof, the method comprising administering to the subject a chimeric protein having a general structure of:
- N terminus-(a)-(b)-(c)-C terminus,
- wherein:
- (a) is a first domain comprising a glucagon-like peptide-1 (GLP-1) receptor agonist comprising an amino acid sequence of SEQ ID NO:
- 91 or variant thereof comprising one or two amino acid mutations with respect to an amino acid sequence of amino acid sequence of SEQ ID NO:
- 91, wherein the GLP-1 receptor agonist is resistant to DPP4 degradation;
- (b) is a linker adjoining the first domain and a second domain wherein the linker comprises a hinge-CH2-CH3 Fc domain;
- and
- (c) is the second domain comprising glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) antagonist comprising an amino acid sequence of selected from SEQ ID NO:
- 97, or variant thereof comprising one or two amino acid mutations with respect to an amino acid sequence of amino acid sequence selected from SEQ ID NO:
- 97, wherein the GIPR antagonist comprises a Proline (P) residue at position 3 with respect to SEQ ID NO:
- 97.
A method of treating or preventing diabetes or obesity in a subject in need thereof, the method comprising administering to the subject an isolated polynucleotide encoding a chimeric protein having a general structure of:
- N terminus-(a)-(b)-(c)-C terminus,
- wherein:
- (a) is a first domain comprising a glucagon-like peptide-1 (GLP-1) receptor agonist comprising an amino acid sequence of SEQ ID NO:
- 91 or variant thereof comprising one or two amino acid mutations with respect to an amino acid sequence of amino acid sequence of SEQ ID NO:
- 91, wherein the GLP-1 receptor agonist is resistant to DPP4 degradation;
- (b) is a linker adjoining the first domain and a second domain wherein the linker comprises a hinge-CH2-CH3 Fc domain;
- and
- (c) is the second domain comprising glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) antagonist comprising an amino acid sequence of selected from SEQ ID NO:
- 97, or variant thereof comprising one or two amino acid mutations with respect to an amino acid sequence of amino acid sequence selected from SEQ ID NO:
- 97, wherein the GIPR antagonist comprises a Proline (P) residue at position 3 with respect to SEQ ID NO:
- 97.
Dependencies are inferred from the claim text.